Artemis Hospital, Gurgaon – India
About Dr. Rahul Naithani
Dr. Rahul Naithani is a dynamic and internationally acclaimed Haematologist and Bone Marrow Transplant expert in India. Dr. Naithani is celebrated for his expertise in both adult and paediatric haematology, having performed over 650 successful Bone Marrow Transplants for a wide range of blood cancers and disorders. A prolific researcher with over 140 publications, he is at the forefront of innovative treatments for Leukaemia, Lymphoma, and bleeding disorders. His commitment to combining cutting-edge research with patient-centric care makes him one of India’s top BMT specialists.
Medical Degrees:
- MBBS
- MD (Paediatrics) - Lady Hardinge Medical College, Delhi
- DM (Clinical Haematology) - All India Institute of Medical Sciences (AIIMS), New Delhi
- FRCP (Edinburgh) - Fellow of the Royal College of Physicians of Edinburgh
- Fellowship in Bone Marrow Transplantation - The Hospital for Sick Children (SickKids), Toronto, Canada
- Specialised Training - St. Jude Children’s Research Hospital, Memphis, USA
- Chief Fellow, Paediatric Haematology-Oncology, University of Toronto (2009-2011)
Major Cancer Types Treated:
- Acute & Chronic Leukaemia (ALL, AML, CML)
- Hodgkin’s & Non-Hodgkin’s Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndromes (MDS)
- Early T-cell Precursor (ETP) ALL
- Erdheim-Chester Disease
- Paediatric Haematology & Oncology
- Aplastic Anaemia
- Thalassaemia & Sickle Cell Disease
- Bleeding & Clotting Disorders
- Immune Thrombocytopenia (ITP) & Autoimmune Haemolytic Anaemia (AIHA)
- Disorders of White Blood Cells and Platelets
- Bone Marrow Transplantation (BMT) - Autologous, Allogeneic, Haploidentical, and MUD (Matched Unrelated Donor)
- Paediatric BMT
- Novel therapeutics (e.g., Venetoclax, Inotuzumab Ozogamicin, Daratumumab)
- Fecal Microbiota Transplantation for transplant-related complications
Current Afiliation:
- Chief – Haematology, Oncology & BMT, Artemis Hospital, Gurugram
- Director & Head, Haematology & BMT, Paras Health, Gurugram (2023-2024)
- Director & Head, Haematology & BMT, Max Healthcare, Saket, Delhi (2011 - 2023)
- Chief Fellow, Paediatric Haematology/Oncology, SickKids Hospital & University of Toronto, Canada (2009 - 2011)
- Specialist Registrar, Department of Haematology, AIIMS, New Delhi (2004 - 2008)
- Academic & Research Roles:
- Executive Editor: Indian Journal of Hematology & Blood Transfusion
- Key Achievements & Contributions:
- Spearheaded the establishment and growth of a major Haematology & BMT programme at Max Healthcare, performing over 650 transplants.
- An exceptionally active researcher with over 140 publications in high-impact national and international journals, contributing significantly to clinical practice.
- Holds leadership positions in key medical societies, influencing haematology practice and policy in India.
National & International Awards:
- European School of Oncology - Best Presentation Award (2008)
- Meena Dhamija Award, API Delhi (2007)
- Indian Society of Haematology & Transfusion Medicine - Second Prize (2006)
- Executive Committee Member, Indian Society of Haematology & Transfusion Medicine (ISHMT)
Published Papers in Medical Journals (Selected Recent):
- Lower-dose venetoclax (LoVe) based regimes in children with acute leukemia, Pediatric Hematology and Oncology, (2024)
- Very low-dose vemurafenib maintenance for cardiac Erdheim Chester disease, Clinical Case Reports, (2024)
- Inotuzumab Ozogamicin in Indian Patients with B-Cell Acute Lymphoblastic Leukemia, Indian Journal of Hematology and Blood Transfusion, (2024)
- Haploidentical Hematopoietic Stem Cell Transplantation in India-Bridging the Gap, Indian Journal of Hematology and Blood Transfusion, (2024)
- Short-course Venetoclax With Standard Chemotherapy Is Effective in Early T-cell Precursor Acute Lymphoblastic Leukemia, Journal of Pediatric Hematology/Oncology, (2023)
- Myelodysplastic Neoplasm: Pathogenesis, Diagnosis and Management, Chapter, (2024)
Notable Cases Handled:
- Dr. Naithani is a pioneer in using novel drug combinations and has successfully salvaged patients with relapsed/refractory leukaemias using innovative agents like venetoclax and daratumumab. He has extensive experience in managing complex, high-risk BMT cases in both children and adults.
- "Dr. Rahul Naithani is more than a doctor; he is a beacon of hope. When my daughter's leukaemia returned, he used a cutting-edge treatment that put her back into remission. His knowledge is immense, and his dedication is truly inspiring. We felt safe under his care at every step."
- "My BMT journey was challenging, but Dr. Naithani's expertise made all the difference. He is a master of his field, incredibly well-read, and always one step ahead. The transplant was a success thanks to his meticulous planning and the wonderful team he leads."
- Patient-Centred Care: Dr. Naithani combines his profound academic knowledge with a deeply compassionate and patient-focused approach. He believes in clear communication and empowering patients with a thorough understanding of their condition and treatment options, ensuring a collaborative journey to recovery.
- Technology & Innovation: As a leading clinical researcher, Dr. Naithani is dedicated to translating the latest scientific discoveries into clinical practice. He is at the forefront of utilising novel targeted therapies and immunotherapies, often in innovative combinations, to improve outcomes for patients with high-risk and relapsed blood cancers.
The costs for advanced haematological treatments are estimates and can vary based on the specific disease, treatment complexity, and hospital stay.
Note: The costs are indicative. For a precise treatment estimate, please connect with the Cancer Rounds team for a detailed evaluation of your case.
| Treatment/Procedure | Estimated Cost (INR) | Estimated Cost (USD) |
| Autologous Bone Marrow Transplant | ₹16,00,000 - ₹22,00,000 | $19,200 - $26,400 |
| Allogeneic Bone Marrow Transplant (Family Donor) | ₹25,00,000 - ₹40,00,000 | $30,000 - $48,000 |
| Matched Unrelated Donor (MUD) BMT | ₹35,00,000 - ₹50,00,000+ | $42,000 - $60,000+ |
| Chemotherapy for Leukaemia/Lymphoma | ₹5,00,000 - ₹18,00,000 (per cycle/phase) | $6,000 - $21,600 |
- Language Support: Dr. Naithani is fluent in English and Hindi. The Cancer Rounds team provides professional interpreters for other languages to ensure clear and comfortable communication.
- Visa & Travel Assistance: The Cancer Rounds team offers comprehensive support for international patients, including visa invitation letters, travel logistics, airport pick-up and drop-off, and accommodation arrangements.
- Pre-treatment Virtual Consultations: We facilitate online video consultations with Dr. Naithani, allowing international patients to receive an expert second opinion and a preliminary treatment plan before travelling to India.
Frequently Asked Questions
Dr. Rahul Naithani is a top expert in Haematology, Haemato-Oncology, and Bone Marrow Transplantation (BMT). He has a special focus on both adult and paediatric haematology, treating conditions like leukaemia, lymphoma, and aplastic anaemia.
Yes, Dr Naithani is a highly qualified Paediatric Haematologist with an MD in Paediatrics and a fellowship in Paediatric BMT from The Hospital for Sick Children (SickKids) in Toronto, one of the world's leading children's hospitals.
Dr. Naithani is a high-volume transplant physician, having successfully performed over 650 Bone Marrow Transplants for various malignant and non-malignant blood disorders. Dr Naithani is a leading BMT expert in India.
Dr. Naithani is the Executive Editor of a major haematology journal and has authored over 140 research articles and publications in prestigious national and international medical journals, contributing significantly to the advancement of haematology.
You can book an appointment for a consultation through the Cancer Rounds team.
Fortis Hospital Gurgaon - India
